How many units of KLOW do I draw?

It depends on how much water is in the vial and the amount of one peptide you are aiming for. With 3 mL in a KLOW 80 mg vial, every 10 units on a U-100 insulin syringe holds 1.667 mg GHK-Cu, 333.3 mcg KPV, 333.3 mcg BPC-157 and 333.3 mcg TB-500. To find the units for a set amount of one peptide, divide that amount by its concentration (mg in vial ÷ mL of water) and multiply by 100. How much to take is a decision for you and your prescriber.

How much bacteriostatic water do I add to a KLOW 80 mg vial?

There is no single right amount. More water makes each draw bigger and easier to measure; less water makes it smaller. With 2 mL, 10 units holds 2.5 mg GHK-Cu, 500 mcg KPV, 500 mcg BPC-157 and 500 mcg TB-500. With 3 mL, 10 units holds 1.667 mg GHK-Cu, 333.3 mcg KPV, 333.3 mcg BPC-157 and 333.3 mcg TB-500. With 5 mL, 10 units holds 1 mg GHK-Cu, 200 mcg KPV, 200 mcg BPC-157 and 200 mcg TB-500.

Can I change the amount of one peptide in KLOW without changing the others?

No. The peptides are mixed in one vial, so the ratio is fixed when the vial is made. Every draw takes the same volume of all of them: drawing more of GHK-Cu also means drawing more of KPV, BPC-157 and TB-500. Adding more or less water changes the draw size, not the ratio. To adjust one peptide on its own you would need it in a separate vial.

How many draws are in a KLOW vial?

A vial mixed with 3 mL holds 300 units, so it gives 30 draws of 10 units or 15 draws of 20 units. All of the peptides run out on the same draw, because each draw takes the same share of each. In practice a little is lost to syringe dead space and the last drops in the vial.

Can I track KLOW in Dose Track?

Yes. Dose Track supports single-vial blends. Save the vial with the mg of each peptide and the water you added; the ratio stays locked, and each draw you log records the amount of every peptide in it. Your log stays on your phone.

KLOW Peptide Blend: How Many Units Per Peptide

Short answer: With 3 mL of bacteriostatic water in a KLOW 80 mg vial (50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500), every 10 units on a U-100 insulin syringe holds 1.667 mg GHK-Cu, 333.3 mcg KPV, 333.3 mcg BPC-157 and 333.3 mcg TB-500. The ratio is fixed, so you cannot change one peptide without changing the others. Amounts are arithmetic on the label, not dose advice.

What is in KLOW?

KLOW is a four-peptide blend sold in one vial: GHK-Cu, KPV, BPC-157 and TB-500. It is the GLOW blend with KPV added. All four are mixed with the same water, so every draw contains all four in the same ratio.

Listings we checked agree on one composition. Check your own label: the per-unit amounts below are only right for a vial with these amounts.

KLOW 80 mg

KLOW 80 mg: commonly labeled as 50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500 (80 mg total).
Peptide	Commonly labeled	Share of vial	Guide
GHK-Cu	50 mg	62.5%	GHK-Cu guide
KPV	10 mg	12.5%	KPV guide
BPC-157	10 mg	12.5%	BPC-157 guide
TB-500	10 mg	12.5%	TB-500 guide

How many units: amount of each peptide per 10 units

The water volume changes how big each draw is, not what is in the vial. The highlighted row is 3 mL.

KLOW 80 mg, U-100 insulin syringe (1 mL = 100 units). Amount of each peptide in every 10 units.
Water added	Units in vial	GHK-Cu / 10 units	KPV / 10 units	BPC-157 / 10 units	TB-500 / 10 units
2 mL	200	2.5 mg	500 mcg	500 mcg	500 mcg
3 mL	300	1.667 mg	333.3 mcg	333.3 mcg	333.3 mcg
5 mL	500	1 mg	200 mcg	200 mcg	200 mcg

What a draw holds at 3 mL

KLOW 80 mg mixed with 3 mL. Draw sizes are examples for the conversion, not doses.
Units drawn	Volume	GHK-Cu	KPV	BPC-157	TB-500
5 units	0.05 mL	833.3 mcg	166.7 mcg	166.7 mcg	166.7 mcg
10 units	0.1 mL	1.667 mg	333.3 mcg	333.3 mcg	333.3 mcg
20 units	0.2 mL	3.333 mg	666.7 mcg	666.7 mcg	666.7 mcg
30 units	0.3 mL	5 mg	1 mg	1 mg	1 mg

For any other vial, water volume or draw, the free peptide blend calculator does the same math for 2 to 5 peptides.

The math

Concentration of each peptide. mg of that peptide ÷ mL of water. For KLOW 80 mg with 3 mL: GHK-Cu 50 ÷ 3 = 16.667 mg/mL, KPV 10 ÷ 3 = 3.333 mg/mL, BPC-157 10 ÷ 3 = 3.333 mg/mL, TB-500 10 ÷ 3 = 3.333 mg/mL.
Volume for the peptide you are targeting. amount ÷ its concentration = mL. Example: 250 mcg of TB-500 is 0.25 ÷ 3.333 = 0.075 mL.
Syringe units. mL × 100 on a U-100 syringe: 0.075 × 100 = 7.5 units.
Everything else in that draw. mL × concentration for each other peptide: 1.25 mg GHK-Cu, 250 mcg KPV and 250 mcg BPC-157.

The amount in the example is there to show the math, not a recommendation. How much to take is a decision for you and your prescriber.

The key limitation: the ratio is fixed

A blend is one solution, so every draw takes the same share of each peptide. In the example above, drawing 7.5 units for 250 mcg of TB-500 also gives 1.25 mg GHK-Cu, 250 mcg KPV and 250 mcg BPC-157. Doubling the draw to 15 units doubles all of them, to 2.5 mg GHK-Cu, 500 mcg KPV and 500 mcg BPC-157. There is no draw that changes one peptide and leaves the others where they are.

More or less water does not help either: it changes how many units each draw is, not the ratio between the peptides. If you need to set the amount of each peptide on its own, they have to be in separate vials (a stack), each with its own single-peptide calculation.

Research status of each peptide

We found no published human study of KLOW as a blend. Below is what is published for each peptide on its own. "Amounts studied" are what a study gave or reported, often by a different route; they are not personalized advice. Confirm anything about your own use with your prescriber.

GHK-Cu

A copper complex of a tripeptide found naturally in human plasma, used in skin-care products. Injectable use is not FDA approved. Most research is in cells, animals and topical products; we found no published controlled human trials of injected GHK-Cu. [1]

Amounts studied: None published for injection.

KPV

Not FDA approved. A tripeptide (lysine-proline-valine) from the end of alpha-MSH. Research is preclinical: one 2008 study reported less colitis in two mouse models when KPV was given in drinking water. We found no published human trials. [2]

Amounts studied: None published in humans.

BPC-157

Not FDA approved. Research is mostly in animals: a 2025 systematic review found 36 studies, 35 of them preclinical. A 2026 systematic review found three small human studies (30 people in total), none with a control group, and rated the certainty of the evidence very low. [3][4][5]

Amounts studied: The only published human amounts come from small uncontrolled reports. One intravenous safety pilot gave 10 mg and then 20 mg infusions to 2 adults. No controlled trial has studied BPC-157 injected under the skin.

TB-500

Not FDA approved. TB-500 is a synthetic copy of a short active region of thymosin beta-4 (N-acetylated LKKTETQ). There are no published human studies of TB-500 itself; research on it is in cells and animals. [6][7]

Amounts studied: None published for TB-500. The only human dosing data are for full-length recombinant thymosin beta-4, a larger and different molecule, given into a vein at 0.05 to 25 mcg/kg in a phase I safety study.

Regulatory status. As of October 2026 none of the peptides in these blends is FDA approved. In July 2026 an FDA advisory committee voted 8 to 6 to recommend adding BPC-157, KPV and TB-500 to the list of substances pharmacies may compound. FDA staff had recommended against it, the vote is not binding, and none has been added yet. [8]

KLOW blend: how many units, and how much of each peptide